Top Page
GlaxoSmithKline
(LSE:GSK)
GlaxoSmithKline (GSK) vs. iShares MSCI United Kingdom ETF (EWC)
GlaxoSmithKline Business Overview & Revenue Model
GlaxoSmithKline Earnings Call Summary
GlaxoSmithKline Financial Statement Overview
| Breakdown | |||||
| TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 31.53B | 31.38B | 30.33B | 29.32B | 34.11B | 34.10B | Gross Profit |
| 22.58B | 22.33B | 21.76B | 19.77B | 22.51B | 22.39B | EBIT |
| 5.09B | 4.02B | 6.75B | 6.43B | 6.20B | 7.78B | EBITDA |
| 8.24B | 6.67B | 9.14B | 8.63B | 7.76B | 10.16B | Net Income Common Stockholders |
| 3.15B | 2.58B | 4.93B | 4.92B | 4.38B | 5.75B |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 4.49B | 3.89B | 5.69B | 7.88B | 4.33B | 6.37B | Total Assets |
| 60.70B | 59.46B | 59.01B | 60.15B | 79.10B | 80.43B | Total Debt |
| 18.43B | 16.99B | 18.02B | 20.99B | 24.17B | 27.15B | Net Debt |
| 13.97B | 13.12B | 15.08B | 17.26B | 19.90B | 20.86B | Total Liabilities |
| 47.05B | 46.38B | 46.21B | 50.05B | 57.76B | 59.62B | Stockholders Equity |
| 14.16B | 13.67B | 13.35B | 10.60B | 15.05B | 14.59B |
| Cash Flow | Free Cash Flow | ||||
| 3.64B | 3.57B | 4.42B | 5.14B | 5.02B | 6.20B | Operating Cash Flow |
| 6.50B | 6.55B | 6.77B | 7.40B | 7.95B | 8.44B | Investing Cash Flow |
| -2.26B | -1.23B | -1.59B | -8.77B | -1.78B | 2.16B | Financing Cash Flow |
| -2.54B | -4.73B | -5.64B | 823.00M | -7.59B | -10.13B |
GlaxoSmithKline Technical Analysis
GlaxoSmithKline Risk Analysis
GlaxoSmithKline Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | £167.75B | 27.43 | 19.90% | 2.46% | 13.74% | 21.45% | |
80 Outperform | £5.88B | 39.56 | 11.12% | 1.90% | 3.94% | 41.63% | |
76 Outperform | £9.47B | 29.31 | 7.78% | 3.19% | 1.85% | 51.77% | |
71 Outperform | £4.62B | 16.53 | 15.79% | 2.75% | 5.83% | 83.35% | |
67 Neutral | £60.17B | 19.24 | 22.52% | 3.17% | 2.57% | -30.13% | |
54 Neutral | $5.34B | 3.36 | -45.10% | 3.39% | 16.81% | -0.03% | |
| $38.90B | 3.79 | 13.12% | 9.18% | ― | ― |
GlaxoSmithKline Corporate Events
GSK plc announced the purchase of 458,818 of its ordinary shares as part of its ongoing share buyback program. The shares, bought at prices ranging from 1,465.00p to 1,485.00p, will be held as treasury shares. This move is part of a non-discretionary agreement with Merrill Lynch International, and it increases the total number of shares held in treasury to 221,857,710. The buyback program is a strategic effort to manage the company’s capital structure and potentially enhance shareholder value.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has announced the repurchase of 453,531 of its ordinary shares as part of its ongoing buyback program. The shares were purchased at prices ranging from 1,485.50p to 1,506.00p and will be held as treasury shares. This move, facilitated by Merrill Lynch International, is part of a strategy to manage the company’s capital structure and return value to shareholders. Following this transaction, GSK holds 221,398,892 shares in treasury, with a total of 4,093,902,697 shares in issue. The buyback program reflects GSK’s commitment to optimizing shareholder returns and maintaining a robust financial position.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has announced the purchase of 356,703 of its own ordinary shares as part of its ongoing buyback program, executed through Merrill Lynch International. This transaction aims to consolidate the company’s share capital and potentially enhance shareholder value. Following this purchase, GSK holds 220,945,361 shares in treasury, with a total of 4,094,356,228 shares in issue, impacting the percentage of voting rights and potentially influencing shareholder decisions under regulatory guidelines.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK plc announced a transaction involving the sale of 29,763 ordinary shares by Sally Jackson, the Senior Vice President of Global Communications and CEO Office. The transaction was conducted on the London Stock Exchange at a price of £15.4447 per share. This sale may have implications for GSK’s stock market activity and could be of interest to stakeholders monitoring executive transactions within the company.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK announced that the European Medicines Agency has accepted its application to expand the use of its RSV vaccine, Arexvy, to adults aged 18 and older. This expansion could significantly impact GSK’s operations and industry positioning by broadening the vaccine’s market reach, potentially benefiting stakeholders by addressing a common virus that affects millions globally. A decision is anticipated in the first half of 2026, and GSK is also seeking similar approvals in the US and Japan.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GlaxoSmithKline (GSK) has announced the purchase of 317,488 of its own ordinary shares as part of its ongoing buyback program. These shares will be held as treasury shares, and the transaction was conducted through Merrill Lynch International. This move is part of a non-discretionary agreement with the broker, initiated on June 4, 2025. Following this purchase, GSK now holds 220,588,658 shares in treasury, with a total of 4,094,694,253 ordinary shares in issue. The buyback is expected to impact the company’s financial structure by potentially increasing shareholder value and optimizing capital allocation.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK announced the purchase of 325,916 of its ordinary shares as part of its ongoing buyback program, executed through Merrill Lynch International. This transaction, which is part of a non-discretionary agreement, increases the total shares held in treasury to over 220 million, representing 5.38% of the company’s voting rights. The buyback is a strategic move to enhance shareholder value and manage capital structure, reflecting positively on GSK’s financial health and market confidence.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK plc announced the sale of 30,000 ordinary shares by James Ford, the Senior Vice President and Group General Counsel for Legal and Compliance. The transaction, conducted on the London Stock Exchange, reflects internal financial activities and may influence stakeholder perceptions regarding the company’s financial strategies.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has announced the purchase of 374,145 of its ordinary shares as part of its ongoing buyback program, executed through its broker Merrill Lynch International. This move is part of a non-discretionary agreement and aims to consolidate the company’s shareholding structure, holding these shares in treasury, which now account for 5.37% of the voting rights. This strategic buyback is expected to enhance shareholder value and optimize the company’s capital structure.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GlaxoSmithKline has announced the repurchase of 348,430 of its ordinary shares as part of its ongoing buyback program, executed through Merrill Lynch International. This transaction, which took place on June 9, 2025, is part of a broader strategy to manage the company’s capital structure and return value to shareholders. The shares will be held as treasury shares, and following this purchase, GSK holds 219,571,109 ordinary shares in treasury. The buyback program is expected to enhance shareholder value and optimize the company’s financial position.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK plc announced the purchase of 342,461 of its own ordinary shares as part of its ongoing buyback program. The shares, purchased through Merrill Lynch International, will be held as treasury shares, increasing the total number of shares held in treasury to 219,222,679. This action is part of a non-discretionary agreement and reflects the company’s strategy to manage its capital structure, potentially impacting shareholder value and market perception.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has announced the repurchase of 355,835 of its own ordinary shares as part of its ongoing buyback program. This transaction, executed through Merrill Lynch International, reflects GSK’s strategy to manage its capital structure and return value to shareholders, holding 218,880,218 shares in treasury post-purchase. The buyback could potentially enhance shareholder value and influence the company’s stock market performance.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £22.90 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has announced the repurchase of 390,000 of its own ordinary shares as part of its ongoing buyback program. The shares were acquired at prices ranging from 1,476.50p to 1,500.00p and will be held as treasury shares, which currently account for 5.33% of the company’s voting rights. This move is part of GSK’s strategy to enhance shareholder value and manage its capital structure effectively.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £22.90 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has announced the purchase of 417,924 of its own ordinary shares as part of its ongoing buyback program. This transaction, executed through Citigroup Global Markets Limited, reflects GSK’s strategy to manage its capital structure and potentially enhance shareholder value. The shares will be held as treasury shares, and the total number of voting rights remains unchanged, allowing stakeholders to assess their interests in the company accurately.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has announced the launch of the second tranche of its £2 billion share buyback program, which aims to return excess capital to shareholders and enhance earnings per share. This tranche, valued at up to £0.45 billion, will be executed independently by Merrill Lynch International and is expected to be completed by September 2025, reflecting GSK’s strategic focus on optimizing shareholder value and its commitment to financial discipline.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has announced the purchase of 564,381 of its own ordinary shares as part of its ongoing buyback program, executed through Citigroup Global Markets Limited. This move is part of a strategy to manage the company’s capital structure and potentially enhance shareholder value, with the shares being held in treasury. Following this transaction, GSK holds 217,716,459 shares in treasury, representing 5.31% of the voting rights, and has a total of 4,097,550,815 shares in issue.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has announced a transaction involving the sale of 77,000 ordinary shares by James Ford, the Senior Vice President and Group General Counsel for Legal and Compliance. The transaction was conducted on the London Stock Exchange on May 30, 2025, at a price of £14.9825 per share. This sale may impact the company’s stock performance and stakeholder perceptions, reflecting internal financial strategies or personal financial planning by the executive.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK plc has announced its total voting rights and capital structure as of May 31, 2025. The company reported an issued share capital of over 4.3 billion shares, with a total of approximately 4.1 billion voting rights. This information is crucial for shareholders to determine their notification obligations under the Financial Conduct Authority’s rules, impacting how they manage their interests in the company.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has announced the purchase of 528,198 of its own ordinary shares, as part of its ongoing buyback program, through Citigroup Global Markets Limited. This transaction, executed on the London Stock Exchange, aims to manage the company’s capital structure and enhance shareholder value, with the shares being held in treasury. Following this purchase, GSK holds 217,152,078 shares in treasury, with a total of 4,098,115,196 shares in issue, reflecting a 5.30% voting rights attributed to treasury shares.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK announced that the US FDA has accepted the New Drug Application for linerixibat, a targeted inhibitor for treating cholestatic pruritus in patients with primary biliary cholangitis (PBC). The application is based on positive results from the GLISTEN phase III trial, which demonstrated significant improvement in symptoms compared to placebo. If approved, linerixibat could address a high unmet medical need for patients suffering from this debilitating condition, potentially enhancing GSK’s position in the hepatology market.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has announced the purchase of 535,953 of its own ordinary shares as part of its ongoing share buyback program, executed through Citigroup Global Markets Limited. This transaction, which follows a non-discretionary agreement initiated in February 2025, increases the company’s treasury shares to 216,623,880, representing 5.29% of the total voting rights. This strategic move is likely to impact GSK’s market positioning by potentially enhancing shareholder value and optimizing capital structure.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK plc has announced the purchase of 535,953 of its own ordinary shares as part of its ongoing buyback program. This transaction, executed through Citigroup Global Markets Limited, reflects GSK’s strategy to manage its capital structure effectively. The shares will be held as treasury shares, and the total number of voting rights in the company remains at 4,098,638,167. This buyback is part of a broader initiative to enhance shareholder value and optimize the company’s financial position.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has announced the repurchase of 530,805 ordinary shares as part of its ongoing buyback program, executed through Citigroup Global Markets Limited. This transaction, which is part of a non-discretionary agreement, increases GSK’s treasury shares to 216,087,927, representing 5.27% of the company’s voting rights. The buyback is a strategic move to optimize capital structure and potentially enhance shareholder value.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK and Spero Therapeutics announced the early termination of the Phase III PIVOT-PO trial for tebipenem HBr due to its efficacy in treating complicated urinary tract infections (cUTIs). This investigational oral antibiotic could become the first oral carbapenem for cUTIs in the US, potentially reducing hospitalizations and healthcare costs. The trial’s success highlights GSK’s expanding anti-infectives portfolio and its commitment to combating antimicrobial resistance. The data will be included in a planned FDA filing in the second half of 2025.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK plc announced the purchase of 523,548 of its own ordinary shares as part of its ongoing buyback program, executed through Citigroup Global Markets Limited. This transaction is part of a non-discretionary agreement and contributes to GSK’s strategy of managing its capital structure, with the purchased shares held as treasury shares. The buyback program is significant for shareholders as it affects the total voting rights and share distribution, with implications for shareholder notifications under the Financial Conduct Authority’s rules.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has announced the repurchase of 537,661 ordinary shares as part of its ongoing buyback program, executed through Citigroup Global Markets Limited. This transaction increases the company’s treasury shares to 215,033,574, representing 5.2444% of the total shares with voting rights, potentially impacting shareholder calculations under the Financial Conduct Authority’s rules.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Blenrep for treating relapsed or refractory multiple myeloma in combination with other therapies. This recommendation follows successful phase III trials showing superior efficacy and safety profiles. If approved, Blenrep combinations could significantly impact treatment options for multiple myeloma, offering a new mechanism of action and addressing unmet needs in both academic and community settings. The decision by the European Commission is expected in Q3 2025, with potential implications for GSK’s market positioning and stakeholders.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £21.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has announced that the US FDA has approved Nucala (mepolizumab) as an add-on maintenance treatment for adults with chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype. This approval, based on the positive results from the MATINEE and METREX phase III trials, marks a significant advancement in COPD treatment, offering hope for improved care for patients who are inadequately controlled on inhaled triple therapy. The approval is expected to impact over a million patients in the US, potentially reducing hospitalizations and emergency department visits. Mepolizumab is the only biologic approved for this patient group, providing a new treatment option for those with a blood eosinophil count starting at 150 cells/μL.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has announced the purchase of 547,990 of its own ordinary shares as part of its ongoing buyback program. This transaction, executed through Citigroup Global Markets Limited, reflects GSK’s strategy to manage its capital structure and potentially enhance shareholder value. The shares will be held as treasury shares, and the purchase contributes to the company’s broader financial strategy, impacting its total voting rights and share distribution.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK plc announced the purchase of 567,590 of its own ordinary shares as part of its ongoing buyback program, executed through Citigroup Global Markets Limited. This transaction, which took place on May 21, 2025, aims to manage the company’s capital structure and enhance shareholder value. Following this purchase, GSK holds a total of 213,947,923 ordinary shares in treasury, with 4,101,310,936 shares remaining in issue. The buyback program reflects GSK’s strategic financial management to optimize its capital allocation and potentially improve its stock market performance.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has announced the purchase of 570,340 of its own ordinary shares as part of its ongoing buyback program. This transaction, executed through Citigroup Global Markets Limited, reflects GSK’s strategic financial management and aims to enhance shareholder value by holding these shares in treasury, thereby potentially impacting the company’s market positioning and stakeholder interests.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK plc announced the acquisition of American Depositary Shares (ADSs) by its Non-Executive Director, Dr. Hal Barron, and SVP and Group General Counsel, James Ford. These acquisitions were made through the reinvestment of dividends in their respective GSK savings plans. The transactions were conducted on the New York Stock Exchange, reflecting GSK’s ongoing commitment to aligning executive interests with shareholder value.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has announced the purchase of 565,355 of its own ordinary shares as part of its ongoing buyback program. These shares, purchased at an average price of 1,394.81 pence, will be held in treasury, contributing to the company’s strategy to manage its capital structure effectively. This transaction reflects GSK’s commitment to returning value to shareholders and maintaining a balanced capital allocation approach.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK plc announced the purchase of 558,662 of its own ordinary shares as part of its ongoing buyback program. The shares, bought at a volume-weighted average price of 1,391.34 pence, will be held as treasury shares. This move is part of a non-discretionary agreement with Citigroup Global Markets Limited and reflects GSK’s strategy to manage its capital structure effectively. Following this transaction, GSK holds 212,244,638 shares in treasury, impacting the total voting rights available to shareholders.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK announced that its drug Blenrep, in combination with other treatments, has been approved by Japan’s Ministry of Health, Labour and Welfare for use in adults with relapsed or refractory multiple myeloma. This approval is based on positive results from the DREAMM-7 and DREAMM-8 phase III trials, which demonstrated superior efficacy in terms of progression-free survival and overall survival compared to standard treatments. The approval marks the second major regulatory endorsement for Blenrep combinations, following the UK’s authorization, and highlights the drug’s potential to redefine treatment outcomes for multiple myeloma patients. Blenrep’s unique mechanism as an anti-BCMA antibody-drug conjugate offers a differentiated approach, with manageable side effects, making it suitable for a wide range of patients in various treatment settings.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has announced the purchase of 569,883 of its own ordinary shares as part of its ongoing share buyback program. This move, executed through Citigroup Global Markets Limited, is part of a non-discretionary agreement and reflects GSK’s strategy to manage its capital structure effectively, potentially enhancing shareholder value and market confidence.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has announced the purchase of 591,951 of its own ordinary shares as part of its ongoing buyback program. The shares, acquired through Citigroup Global Markets Limited, will be held as treasury shares. This move is part of a non-discretionary agreement initiated in February 2025, and since then, GSK has bought back a total of 42,045,790 shares. The buyback program aims to optimize the company’s capital structure and return value to shareholders, potentially impacting GSK’s market positioning and shareholder interests.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £21.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GlaxoSmithKline (GSK) has announced the repurchase of 783,700 of its ordinary shares as part of its ongoing buyback program, executed through Citigroup Global Markets Limited. This transaction is part of a non-discretionary agreement initiated in February 2025, and the purchased shares will be held as treasury shares. The buyback is a strategic move to optimize the company’s capital structure and potentially enhance shareholder value.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has announced its acquisition of efimosfermin alfa from Boston Pharmaceuticals, a promising phase III-ready specialty medicine aimed at treating steatotic liver disease (SLD), a condition affecting up to 5% of the global population. This acquisition, valued at up to $2 billion, significantly enhances GSK’s hepatology pipeline, offering potential new treatment options for SLD and aligning with the company’s R&D focus on immune system-related science. Efimosfermin has shown potential to reverse liver fibrosis and improve patient outcomes, with a first launch expected in 2029, positioning GSK to address a significant unmet medical need and potentially save the US healthcare system substantial costs over the next two decades.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK plc announced the acquisition of ordinary shares by several of its senior executives, including the CEO and CFO, under the company’s Share Reward Plan. This transaction, conducted on the London Stock Exchange, reflects the company’s ongoing commitment to aligning the interests of its leadership with those of its shareholders, potentially enhancing stakeholder confidence and reinforcing its market position.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK, in partnership with iTeos Therapeutics, has decided to terminate the development of belrestotug, an anti-TIGIT monoclonal antibody, after interim analyses from phase 2 studies failed to meet efficacy criteria. This decision impacts GSK’s oncology strategy, which includes a shift towards other promising therapeutic areas, potentially affecting stakeholders involved in the belrestotug program.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has announced the repurchase of 812,010 ordinary shares as part of its ongoing buyback program, executed through Citigroup Global Markets Limited. This move is part of a larger strategy to manage its capital structure, with the company now holding over 209 million shares in treasury. The buyback is expected to enhance shareholder value and reflects GSK’s confidence in its financial health and future prospects.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has announced the purchase of 650,432 of its own ordinary shares as part of its ongoing share buyback program. This move is part of a non-discretionary agreement with Citigroup Global Markets Limited, aiming to enhance shareholder value by reducing the number of shares in circulation, which could potentially increase earnings per share and improve market perception.
GSK plc has announced the purchase of 699,344 of its own ordinary shares as part of its ongoing buyback program, executed through Citigroup Global Markets Limited. This move is part of a non-discretionary agreement initiated in February 2025, and it reflects the company’s strategy to manage its capital structure effectively. The shares will be held as treasury shares, and this transaction increases the total number of shares held in treasury to 206,209,407. The buyback program is a strategic effort to enhance shareholder value and optimize the company’s financial position.
GSK has announced the purchase of 709,955 of its own ordinary shares as part of its ongoing buyback program. This transaction, executed through Citigroup Global Markets Limited, reflects GSK’s strategic financial management and aims to enhance shareholder value by holding these shares in treasury. The buyback program underscores GSK’s commitment to optimizing its capital structure and potentially improving its earnings per share, thereby strengthening its position in the healthcare industry.
GSK plc has announced its total voting rights and capital structure as of April 30, 2025, in accordance with the Financial Conduct Authority’s rules. The company’s issued share capital consists of over 4.3 billion ordinary shares, with a total of 4.1 billion voting rights available to shareholders. This update is crucial for shareholders to calculate their interests and comply with regulatory requirements.
GSK announced positive results from the MATINEE phase III trial for Nucala (mepolizumab) in treating chronic obstructive pulmonary disease (COPD). The trial demonstrated significant reductions in COPD exacerbations, including a 21% reduction in moderate/severe exacerbations and a 35% reduction in exacerbations leading to emergency visits or hospitalizations. These findings highlight Nucala’s potential to improve patient outcomes and address a major healthcare challenge, as COPD-related hospitalizations are projected to become a leading cause of medical admissions.
GSK has announced the purchase of 685,000 of its own ordinary shares as part of its ongoing buyback program. This transaction, executed through Citigroup Global Markets Limited, is part of a non-discretionary agreement and reflects GSK’s strategy to manage its capital structure and enhance shareholder value. Following this purchase, GSK holds over 204 million shares in treasury, with a total of over 4.1 billion shares in issue, excluding treasury shares. This move is likely to impact the company’s stock liquidity and could influence shareholder decisions regarding their interests in the company.
GSK reported a strong start to 2025 with significant growth in sales, profits, and earnings, driven by its Specialty Medicines segment. The company achieved a 4% increase in total Q1 sales to £7.5 billion, with notable contributions from oncology and respiratory medicines. GSK also highlighted its pipeline progress, expecting five major FDA product approvals in 2025, and emphasized its commitment to shareholder returns with a declared dividend and a share buyback program. The company remains confident in its 2025 guidance, projecting turnover growth of 3% to 5% and core operating profit growth of 6% to 8%, supported by strategic investments in R&D and operational efficiencies.
GSK has announced the purchase of 688,703 of its own ordinary shares as part of its ongoing buyback program, executed through Citigroup Global Markets Limited. This move, which is in line with a non-discretionary agreement established earlier in the year, is aimed at consolidating the company’s shareholding structure, potentially enhancing shareholder value and reflecting confidence in its financial stability.
GSK has announced the purchase of 824,200 of its own ordinary shares as part of its ongoing share buyback program, facilitated by Citigroup Global Markets Limited. This move is part of a non-discretionary agreement aimed at optimizing the company’s capital structure, potentially enhancing shareholder value and reflecting confidence in the company’s financial health.
GSK has announced the purchase of 715,130 of its own ordinary shares as part of its ongoing buyback program. This transaction, executed through Citigroup Global Markets Limited, is part of a non-discretionary agreement and reflects GSK’s strategy to manage its capital structure effectively. The shares will be held as treasury shares, contributing to the company’s financial flexibility and potentially enhancing shareholder value.
GSK has announced the repurchase of 711,400 of its ordinary shares as part of its ongoing buyback program, executed through Citigroup Global Markets Limited. This move, which is part of a non-discretionary agreement, aims to manage the company’s capital structure and return value to shareholders, potentially enhancing shareholder confidence and stabilizing share prices.
GSK plc announced the purchase of 684,200 of its own ordinary shares as part of its ongoing buyback program. This transaction, executed through Citigroup Global Markets Limited, reflects GSK’s strategic financial management and commitment to enhancing shareholder value. The shares will be held as treasury shares, and the total number of voting rights in the company remains unchanged at 4,115,579,330. This move is part of a broader strategy to optimize capital allocation and improve earnings per share, potentially impacting investor confidence and market perception positively.
GSK has announced the UK MHRA’s approval of Blenrep combinations for treating relapsed/refractory multiple myeloma, marking the first global authorization in this setting. The approval is based on superior efficacy results from the DREAMM-7 and DREAMM-8 phase III trials, which demonstrated significant improvements in progression-free and overall survival compared to standard treatments. This development positions Blenrep as a potentially transformative therapy in the treatment landscape, offering a differentiated mechanism of action and addressing the urgent need for more effective multiple myeloma treatments.
GSK plc has announced an increase in notional interest in its ordinary shares for several of its senior executives, including the CEO and CFO, following the reinvestment of dividends paid to shareholders. This transaction, conducted on the London Stock Exchange, reflects the company’s ongoing commitment to aligning executive interests with shareholder value, potentially impacting its market positioning and stakeholder confidence.
GSK announced that the US Advisory Committee on Immunization Practices has recommended the use of its RSV vaccine, Arexvy, for adults aged 50-59 who are at increased risk for severe RSV disease. This recommendation, which follows a successful phase III trial, could benefit over 13 million adults in the US and marks an expansion from previous recommendations for older age groups. The approval of this recommendation could significantly impact GSK’s operations by broadening the market for its RSV vaccine and offering protection to a larger segment of the population vulnerable to severe RSV outcomes.
GSK announced that its 5-in-1 meningococcal vaccine, Penmenvy, received a positive recommendation from the US Advisory Committee on Immunization Practices for use in individuals over 10 years old. This recommendation, if adopted, could simplify the vaccination process by reducing the number of injections required, potentially improving immunization rates among US adolescents and young adults. The vaccine, which combines components of GSK’s existing vaccines Bexsero and Menveo, is set to be available in the US by summer 2025. This development positions GSK to strengthen its market presence in the US, particularly in the MenB vaccine segment, where it already holds a significant share.
GSK has announced the purchase of 676,221 of its own ordinary shares as part of its ongoing buyback program. This transaction, conducted through Citigroup Global Markets Limited, reflects the company’s strategy to manage its capital structure and return value to shareholders. The shares will be held as treasury shares, and the total number of voting rights remains unchanged, providing stakeholders with a stable basis for their investment calculations.
GSK PLC announced the purchase of 914,000 of its ordinary shares as part of its ongoing buyback program, executed through Citigroup Global Markets Limited. The shares will be held as treasury shares, contributing to the company’s strategy to manage its capital structure effectively. This move is part of a non-discretionary agreement with the broker, reflecting GSK’s commitment to optimizing shareholder value and maintaining a robust financial position.
GSK plc announced the acquisition of ordinary shares by two key personnel, David Redfern, President of Corporate Development, and Victoria Whyte, Company Secretary. The shares were acquired following the reinvestment of dividends paid on April 10, 2025, and the transactions were conducted on the London Stock Exchange. This move reflects the company’s ongoing commitment to shareholder value and may positively impact investor confidence.
GSK has announced the purchase of 918,500 of its own ordinary shares as part of its ongoing buyback program, executed through Citigroup Global Markets Limited. This move is part of a strategy to manage the company’s capital structure and return value to shareholders, with the purchased shares being held as treasury shares. The transaction reflects GSK’s commitment to enhancing shareholder value and maintaining a robust financial position.
GSK plc announced the acquisition of American Depositary Shares (ADSs) by several of its independent non-executive directors, including Elizabeth McKee Anderson, Charles Bancroft, Dr. Hal Barron, Dr. Anne Beal, Dr. Harry Dietz, Dr. Jesse Goodman, and Dr. Jeannie Lee. These acquisitions were made following the reinvestment of dividends paid to shareholders on April 10, 2025. The transactions were conducted on the New York Stock Exchange at a price of $34.1210 per share. This move reflects the directors’ confidence in the company’s future performance and could potentially strengthen GSK’s market position by aligning the interests of its leadership with those of its shareholders.
GSK plc announced the purchase of 1,286,688 of its own ordinary shares as part of its ongoing buyback program. The shares, bought at prices ranging from 1,268.00p to 1,299.50p, will be held in treasury. This move is part of a non-discretionary agreement with Citigroup Global Markets Limited, initiated in February 2025, and highlights GSK’s strategy to manage its capital structure and return value to shareholders.
GSK announced the acquisition of ordinary shares by several of its top executives under the company’s Share Reward Plan. This move, involving key figures such as the CEO and CFO, signifies a strategic alignment of management interests with shareholder value, potentially strengthening stakeholder confidence and enhancing the company’s market positioning.
GSK has announced the purchase of 864,000 of its own ordinary shares as part of its ongoing buyback program. The shares, acquired through Citigroup Global Markets Limited, will be held as treasury shares. This move is part of a non-discretionary agreement and contributes to the company’s strategy to manage its capital structure, potentially impacting shareholder value and market perception.
GlaxoSmithKline (GSK) has announced a significant transaction involving the repurchase of 1,519,276 of its own ordinary shares, which will be held as treasury shares. This move is part of GSK’s ongoing buyback program, executed through Citigroup Global Markets Limited. The buyback is aimed at enhancing shareholder value and optimizing the company’s capital structure. Following this transaction, GSK holds a total of 194,312,216 ordinary shares in treasury, with the total number of voting rights standing at 4,120,914,866.
GSK has announced the purchase of 1,035,000 of its own ordinary shares, as part of its ongoing buyback program, through Citigroup Global Markets Limited. The shares, bought at an average price of 1,345.28 pence, will be held as treasury shares. This transaction, part of a non-discretionary agreement, reflects GSK’s strategy to optimize its capital structure and potentially enhance shareholder value. The company now holds 192,792,940 shares in treasury, with 4,122,434,142 shares in issue, impacting the total voting rights available to shareholders.
GSK has announced the purchase of 1,454,000 of its own ordinary shares as part of its ongoing buyback program, executed through Citigroup Global Markets Limited. This move is part of a non-discretionary agreement initiated in February 2025, and the shares will be held as treasury shares. The buyback program is a strategic effort to manage the company’s capital structure and return value to shareholders, reflecting GSK’s confidence in its financial health and future prospects.
GSK has announced the repurchase of 808,000 of its ordinary shares as part of its ongoing buyback program. This transaction, facilitated by Citigroup Global Markets Limited, reflects GSK’s strategy to enhance shareholder value and optimize its capital structure. The shares, purchased at prices ranging from 1,413.00p to 1,468.50p, will be held as treasury shares, contributing to a total of 190,303,940 shares in treasury. This move underscores GSK’s commitment to returning value to its shareholders and maintaining a strong financial position.
GSK has announced the purchase of 739,200 of its own ordinary shares as part of its ongoing share buyback program. This move, executed through Citigroup Global Markets Limited, reflects GSK’s strategy to optimize its capital structure and enhance shareholder value. The shares will be held as treasury shares, contributing to the company’s financial flexibility and potentially impacting its market positioning by reducing the number of shares available in the market.
GSK has announced the purchase of 819,550 of its own ordinary shares as part of its ongoing buyback program. This transaction, executed through Citigroup Global Markets Limited, reflects GSK’s strategy to manage its capital structure and return value to shareholders. The shares will be held as treasury shares, contributing to the company’s financial flexibility and potentially impacting shareholder voting rights.
GSK has announced a recent transaction involving the repurchase of 630,000 of its ordinary shares, as part of its ongoing buyback program. This move, executed through Citigroup Global Markets Limited, aims to consolidate the company’s share capital and potentially enhance shareholder value by holding these shares in treasury. The buyback reflects GSK’s strategic financial management and may influence shareholder interest calculations under regulatory guidelines.
GSK plc has announced its total voting rights and capital as of March 31, 2025, in compliance with the Financial Conduct Authority’s rules. The company’s issued share capital consists of over 4.3 billion shares, with 187 million held in treasury, resulting in a total of approximately 4.1 billion voting rights. This information is crucial for shareholders to determine their notification requirements under regulatory guidelines.
GSK announced the purchase of 836,600 of its own ordinary shares as part of its ongoing buyback program, executed through Citigroup Global Markets Limited. This action is part of a non-discretionary agreement initiated in February 2025, and the shares will be held in treasury, impacting the company’s share structure and potentially influencing shareholder value.
GSK has announced the purchase of 834,200 of its own ordinary shares, which will be held as treasury shares. This transaction is part of the company’s ongoing buyback program, executed through Citigroup Global Markets Limited. The buyback is aimed at optimizing the company’s capital structure and enhancing shareholder value. Following this purchase, GSK holds a total of 186,470,590 ordinary shares in treasury, with 4,128,751,142 shares in issue. This move may influence shareholder voting rights and is a strategic step in GSK’s financial management.
GSK plc has announced the release of American Depositary Shares (ADSs) for several of its non-executive directors following the termination of the GSK Non-Executive Director Share Allocation Arrangements. The directors, including Charles Bancroft, Dr Anne Beal, Dr Hal Dietz, and Dr Jesse Goodman, have received their respective ADSs, with a portion withheld for tax purposes. These shares will be held by the directors until their retirement from the board, reflecting a strategic move in managing executive compensation and aligning with shareholder interests.
GSK plc has announced the purchase of 847,000 of its own ordinary shares as part of its ongoing buyback program. This transaction, executed through Citigroup Global Markets Limited, reflects GSK’s strategic financial management and may influence shareholder value by reducing the number of shares in circulation, potentially increasing earnings per share.
GlaxoSmithKline (GSK) has announced the purchase of 847,000 of its own ordinary shares as part of its ongoing buyback program. The shares, acquired through Citigroup Global Markets Limited, will be held as treasury shares, contributing to a total of 184,789,390 shares in treasury. This move is part of a non-discretionary agreement initiated on 24 February 2025, and since then, GSK has repurchased a total of 15,719,087 shares. The buyback program is a strategic effort to manage the company’s capital structure and potentially enhance shareholder value.
GSK has announced the purchase of 835,000 of its own ordinary shares as part of its ongoing buyback program, executed through Citigroup Global Markets Limited. This move, which involves holding the shares in treasury, is part of a non-discretionary agreement initiated in February 2025, and it reflects GSK’s strategy to manage its capital structure and enhance shareholder value.
GSK plc announced the purchase of 587,100 of its own ordinary shares as part of its ongoing share buyback program. The shares were acquired at prices ranging from 1,482.00p to 1,516.00p, with a volume-weighted average price of 1,490.87p. This transaction, executed through Citigroup Global Markets Limited, adds to the 14,037,087 shares already repurchased since February 2025, reflecting GSK’s strategy to enhance shareholder value and optimize its capital structure.
GSK announced that the US FDA has approved Blujepa (gepotidacin), a first-in-class oral antibiotic for treating uncomplicated urinary tract infections (uUTIs) in female adults and pediatric patients aged 12 and older. This approval marks a significant milestone as Blujepa is the first new class of oral antibiotics for uUTIs in nearly 30 years, addressing the growing issue of drug-resistant bacteria. The approval is based on positive results from phase III EAGLE-2 and EAGLE-3 trials, which demonstrated Blujepa’s efficacy and safety compared to the standard treatment, nitrofurantoin. The commercial launch in the US is planned for the second half of 2025, and the development has been partially funded by US federal agencies.
GSK announced that the European Medicines Agency has accepted its application to expand the use of Nucala (mepolizumab) for treating COPD with an eosinophilic phenotype. The application is backed by the successful phase III MATINEE trial, which demonstrated a significant reduction in moderate/severe exacerbations in COPD patients. If approved, Nucala could become the first monthly biologic treatment for COPD, addressing a major need for targeted therapies in a disease affecting over 40 million people in Europe.
GSK has announced the purchase of 570,000 of its own ordinary shares as part of its ongoing buyback program, executed through Citigroup Global Markets Limited. This move is part of a non-discretionary agreement and reflects GSK’s strategic approach to managing its capital structure, potentially enhancing shareholder value and signaling confidence in the company’s financial health.
GSK plc announced transactions involving the purchase of shares by several of its board members, including Sir Jonathan Symonds, Wendy Becker, Elizabeth McKee Anderson, Charles Bancroft, Dr Hal Barron, Dr Anne Beal, Dr Hal Dietz, and Dr Jesse Goodman. These transactions, conducted on March 20, 2025, involved the acquisition of both Ordinary Shares on the London Stock Exchange and American Depositary Shares on the New York Stock Exchange. The purchases reflect confidence in the company’s future prospects and may influence investor perception positively.
GSK plc has announced the purchase of 565,320 of its own ordinary shares as part of its ongoing buyback program. This transaction, executed through Citigroup Global Markets Limited, reflects GSK’s strategic move to manage its capital structure and potentially enhance shareholder value by holding these shares in treasury.
GSK has announced the purchase of 556,200 of its own ordinary shares as part of its ongoing buyback program, executed through Citigroup Global Markets Limited. This transaction, which took place on March 19, 2025, is part of a non-discretionary agreement and highlights GSK’s strategic efforts to manage its capital structure and enhance shareholder value. The shares will be held as treasury shares, and the total number of voting rights remains unchanged at 4,133,820,322, providing stakeholders with a clear understanding of their shareholding status.
GSK has announced the purchase of 552,000 of its own ordinary shares as part of its ongoing share buyback program, executed through Citigroup Global Markets Limited. This transaction is part of a broader strategy to manage capital structure and return value to shareholders, reflecting GSK’s commitment to maintaining a robust financial position and enhancing shareholder value.
GSK has announced the purchase of 745,425 of its own ordinary shares as part of its ongoing buyback program, executed through Citigroup Global Markets Limited. This transaction, which took place on 17 March 2025, reflects GSK’s strategic initiative to manage its capital structure and enhance shareholder value by holding these shares in treasury, thereby potentially impacting the company’s stock market performance and investor relations.